pertussis epidemiology forecast insight

DelveInsight’s ‘Pertussis - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the disease, historical and forecasted Pertussis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

Geographies Covered

• The United States
• EU5 (Germany, Spain, Italy, France, and United Kingdom)
• Japan
• China

Study Period: 2021-2034

Pertussis Understanding

Pertussis, literally meaning “a violent cough,” and also known as whooping cough, or “the cough of 100 days,” is an acute respiratory infection caused by Bordetella pertussis. First discovered in the Paris epidemic of 1578, pertussis is characterized by a paroxysmal cough lasting ≥2 weeks, an inspiratory whoop, posttussive emesis, and posttussive syncope.

Its common name, whooping cough, is derived from the sound caused by a partially closed glottis obstructing a forceful inspiration. Although pertussis is typically considered a childhood disease, infection rates in adults and adolescents have risen, currently accounting for more than half of all reported cases.

Bordetella pertussis, the causative organism, was discovered in 1906, and a vaccine was developed in the 1940s. Before the pertussis vaccine was developed, pertussis was a major cause of infant morbidity and mortality. Immunity wanes to 50% 12 years after completing a vaccination series. Immunocompromised persons can also contract Bordetella bronchiseptica, which typically affects animals and is commonly known as “a kennel cough.

The diagnosis is based on signs and symptoms and by culture, PCR, and serology. B. pertussis is transmitted by aerosols and infects the ciliated epithelium of the airways. There is no further dissemination of the infection, but bacterial toxins produced in the respiratory tract contribute to local and systemic disease pathogenesis. Despite several decades of research, there are still significant gaps in understanding the role and activity of B. pertussis virulence factors and the pathogenesis of pertussis disease, especially the severe disease in young infants. However, the development of new animal models in recent years and the possible implementation of human volunteer experiments soon provide the opportunity to increase the basic understanding of pertussis and hopefully to develop novel effective vaccines and therapeutics.

Pertussis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Age-specific vaccine immunization rate in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China market from 2021 to 2034.

Key Findings

This section provides glimpse of the pertussis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

• The total vaccine coverage population of Pertussis in the 7MM and China was 65,837,354 in 2020.
• The age-specific vaccine coverage case of Pertussis in the United States was estimated to be 20,058,055 in 2020.
• Among the EU5 countries, Germany had the highest vaccinations followed by France (2,650,337) and Italy (2,303,388). In contrast, the UK had the lowest vaccinations (1,795,059) in 2020.
• Japan accounted for 1,789,783 vaccinated population in 2020, and is estimated to decrease by 2034 owing to the decline in population.
• In China, the number of vaccinated population is expected to decline. The population was estimated to be 31,783,613 in 2020.
• The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China – Pertussis Epidemiology
• The epidemiology segment also provides the Pertussis epidemiology data and findings across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

Scope of the Report

• The report covers the descriptive overview of Pertussis, explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the historical and forecasted patient pool covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.
• The report assesses the disease risk and burden and highlights the unmet needs of Pertussis.
• The report provides the segmentation of the disease epidemiology for the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China by age-specific vaccine immunization.

Report Highlights

• Ten Year Forecast of Pertussis
• The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China Coverage
• Total Age-Specific Vaccination Coverage of Pertussis.
• Total vaccinated population of Pertussis.

Analyst Comments

Among the 7MM and China, vaccination coverage for children is reported to be high. In comparison, the booster vaccination compliance among adults is reported to be low owing to the fact, the above mentioned regions are high income countries. Moreover, VCR is quite low among the adults. Furthermore, the overall Pertussis Vaccination coverage has declined since measures to control the spread of COVID-19 were introduced. It is further recommended to encourage parents about the importance of immunisation against pertussis at the optimal time to protect the babies since birth. With the increasing awareness, updation of immunzation recommendation and entry of emerging vaccines are expected to increase the vaccination coverage rate over the period of time in the 8MM.

Key Questions Answered

• What is the disease risk, burden and unmet needs of Pertussis?
• What is the historical Pertussis patient pool in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), China and Japan?
• What would be the forecasted patient pool of Pertussis at the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China level?
• What will be the growth opportunities in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China with respect to the patient population pertaining to Pertussis?
• At what CAGR the population is expected to grow in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China during the forecast period (2025-2034)?

Reasons to buy

The Pertussis report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China Pertussis market.
• Quantify patient share distribution in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China for Pertussis.
• The Pertussis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Pertussis epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population